Trofosfamide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Trofosfamide
Accession Number
DB12902
Type
Small Molecule
Groups
Investigational
Description

Trofosfamide has been used in trials studying the treatment of Ependymomas, Medulloblastomas, Sarcoma, Soft Tissue, Supratentorial PNETs, and Recurrent Brain Tumors.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
H64JRU6GJ0
CAS number
22089-22-1
Weight
Average: 323.58
Monoisotopic: 322.0171479
Chemical Formula
C9H18Cl3N2O2P
InChI Key
UMKFEPPTGMDVMI-UHFFFAOYSA-N
InChI
InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2
IUPAC Name
2-[bis(2-chloroethyl)amino]-3-(2-chloroethyl)-1,3,2lambda5-oxazaphosphinan-2-one
SMILES
ClCCN(CCCl)P1(=O)OCCCN1CCCl

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Trofosfamide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Trofosfamide.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Trofosfamide.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Trofosfamide.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Trofosfamide.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trofosfamide.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Trofosfamide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Trofosfamide.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Trofosfamide.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Trofosfamide.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Trofosfamide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Trofosfamide.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Trofosfamide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Trofosfamide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trofosfamide.Approved, Investigational
FingolimodTrofosfamide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Trofosfamide.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Trofosfamide.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Trofosfamide.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Trofosfamide.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Trofosfamide.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Trofosfamide.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Trofosfamide.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Trofosfamide.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Leflunomide.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Trofosfamide.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Natalizumab.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Trofosfamide.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Trofosfamide.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Trofosfamide.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Trofosfamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trofosfamide.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Trofosfamide.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Rabies virus inactivated antigen, A.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Trofosfamide.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Trofosfamide.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Trofosfamide.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Trofosfamide.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Trofosfamide.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Trofosfamide.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trofosfamide.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Trofosfamide.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Trofosfamide.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Trofosfamide.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Trofosfamide.Investigational
TofacitinibTrofosfamide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Trofosfamide.Approved, Investigational
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Trofosfamide.Approved
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Trofosfamide.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
65702
PubChem Substance
347829054
ChemSpider
59129
ChEBI
135381
ChEMBL
CHEMBL462019
ATC Codes
L01AA07 — Trofosfamide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
2, 3Active Not RecruitingTreatmentEpendymomas / Medulloblastomas / Recurrent Brain Tumors / Supratentorial PNETs1
3RecruitingTreatmentSoft Tissue Sarcoma (STS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility12.0 mg/mLALOGPS
logP1.4ALOGPS
logP0.98ChemAxon
logS-1.4ALOGPS
pKa (Strongest Basic)0.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity72.72 m3·mol-1ChemAxon
Polarizability29.81 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as isofamides. These are oxazaphospholanes containing the isofamide skeleton. Isofamide is a heterocyclic compound made up of a 1,3,2-oxazaphospholane, where the phosphorus atom is part of a phosphodiamide group, and the oxazaphospholane is substituted by two haloalkyl chains.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazaphosphinanes
Sub Class
Isofamides
Direct Parent
Isofamides
Alternative Parents
Nitrogen mustard compounds / Phosphoric monoester diamides / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Alkyl chlorides
Substituents
Isofamide / Nitrogen mustard / Phosphoric monoester diamide / Organic phosphoric acid derivative / Organic phosphoric acid amide / Azacycle / Oxacycle / Hydrocarbon derivative / Organic oxide / Organooxygen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 19:08 / Updated on November 09, 2017 05:14